22nd Jan 2024 The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer
12th Sep 2023 A plain language summary describing the effect of rapidly rising prostate-specific antigen (PSA) levels on how long men with a type of advanced prostate cancer live and their healthcare costs
10th Aug 2023 A plain language summary looking at whether declines in prostate-specific antigen level indicates how long patients with advanced prostate cancer will live when treated with enzalutamide
12th Apr 2023 Plain Language Summary: managing metastatic prostate cancer by integrating radium-223 therapy